Enjoy complimentary customisation on priority with our Enterprise License!
The colorectal cancer therapeutics market share is expected to increase to USD 2.45 bn from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.43%.
This colorectal cancer therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers colorectal cancer therapeutics market segmentation by type (targeted therapy, immunotherapy, and chemotherapy) and geography (North America, Europe, Asia, and Rest of World (ROW)).
Download the Free Report Sample to Unlock the Colorectal Cancer Therapeutics Market Size for the Forecast Period and Other Important Statistics
The colorectal cancer therapeutics market report also offers information on several market vendors, including Accord Healthcare Ltd., Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG, Biocon Ltd., Bristol-Myers Squibb Co., CK Hutchison Holdings Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Hetero Drugs Ltd., Hikma Pharmaceuticals Plc, Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. among others.
Technavio categorizes the global colorectal cancer therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the colorectal cancer therapeutics market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the colorectal cancer therapeutics market encompasses successful business strategies deployed by the key vendors. The colorectal cancer therapeutics market is fragmented and the vendors are deploying growth strategies such as investment in R&D to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The colorectal cancer therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the colorectal cancer therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The increasing geriatric population is notably driving the colorectal cancer therapeutics market growth, although factors such as patent expiration of novel therapeutics may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the colorectal cancer therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Colorectal Cancer Therapeutics Market Driver
One of the key factors driving the global colorectal cancer therapeutics market growth is the increasing geriatric population. According to the CDC, more than 90% of colorectal cancer cases occur in people in the age group of 50 years and above. As per the data collected by the World Bank and National Institutes of Health (NIH), the percentage of the geriatric population is expected to grow from 9.3% in 2020 to approximately 17% by 2050 globally. In addition, according to the US Census Bureau, the population aged 65 years and above this is expected to rise to 1,566 million by 2050. Hence, the increase in the number of colorectal cancer cases among the growing geriatric population is expected to increase and impel the growth of the market in focus during the forecast period.
Key Colorectal Cancer Therapeutics Market Trend
Development of small molecule kinase inhibitors is one of the key colorectal cancer therapeutics market trends that is expected to impact the industry positively in the forecast period. Several pharmaceutical companies are focusing on the development of safe, low-cost, and easy to administer small molecule drugs. Kinase inhibitors halt the protein phosphorylation process in cancer cells by blocking protein kinases. Regorafenib is the only kinase inhibitor available for the treatment of colorectal cancer. Hence, various pharmaceutical companies are developing kinase inhibitors for the treatment of colorectal cancer. For instance, F. Hoffmann-La Roche Ltd is conducting Phase II clinical trials on Entrectinib, a kinase inhibitor for the treatment of colorectal cancer. Such factors are expected to further support the market growth in the coming years.
Key Colorectal Cancer Therapeutics Market Challenge
One of the key challenges to the global colorectal cancer therapeutics market growth is the patent expiration of novel therapeutics. According to the World Trade Organization's TRIPS agreement (Agreement on Trade-Related Aspects of Intellectual Property Rights), innovators can get a term of 20 years of exclusive patent rights on their novel pharmaceutical therapeutics from the date of application filing in the US and Europe. As a result, pharmaceutical companies sell their innovator products, especially biologics, at a high price until their patent expiration. However, the loss of patents of biologics can open opportunities for biosimilars for entry in the market, thereby increasing competition, which decreases the price of the original biologic therapeutics. Thus, the expiration of patents and other intellectual property rights of therapeutics such as AVASTIN (bevacizumab), VECTIBIX (panitumumab), and ZALTRAP (ziv-Aflibercept) is expected to hamper the growth of the market during the forecast period.
This colorectal cancer therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
For more insights on the market share of various regions Request for a FREE sample now!
36% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for colorectal cancer therapeutics in North America. Market growth in this region will be faster than the growth of the market in ROW.
The increase in demand for colorectal cancer therapeutics due to the high incidence of colorectal cancer will facilitate the colorectal cancer therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
To gain further insights on the market contribution of various segments Request for a FREE sample
The colorectal cancer therapeutics market share growth by the targeted therapy segment will be significant during the forecast period. The expected marketing approvals of targeted biologics are also expected to drive the growth of the segment further in the coming years.
This report provides an accurate prediction of the contribution of all the segments to the growth of the colorectal cancer therapeutics market size and actionable market insights on post COVID-19 impact on each segment.
Breast Cancer Therapeutics market - The market share is expected to increase by USD 13.85 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.95%.
Gynecological Cancers Therapeutics market - The market size is predicted to surge to USD 14.22 billion from 2021 to 2026 at a CAGR of 14.67%.
Oral Cancer Therapeutics market - The market share is expected to increase by USD 1.14 billion from 2021 to 2026, and the market's growth momentum will decelerate at a CAGR of 7.5%.
Throat Cancer Therapeutics market - The market size is predicted to surge to USD 1.82 billion from 2021 to 2026 at a CAGR of 6.7%.
Lung Cancer Therapeutics market - The market share has the potential to grow by USD 6.79 billion during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 6.47%.
|
Colorectal Cancer Therapeutics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.43% |
|
Market growth 2022-2026 |
$ 2.45 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
4.15 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 36% |
|
Key consumer countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
Accord Healthcare Ltd., Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG, Biocon Ltd., Bristol-Myers Squibb Co., CK Hutchison Holdings Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Hetero Drugs Ltd., Hikma Pharmaceuticals Plc, Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
